WDB COCO CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,515 JPY | 0.00% |
|
-0.77% | -2.80% |
| 2019 | WDB coco Co., Ltd. has completed an IPO in the amount of ¥875.16 million. | CI |
| 2019 | WDB coco Co., Ltd. has filed an IPO. | CI |
| Sales 2024 * | 4.6B 29.1M 2.42B | Sales 2025 * | 5.1B 32.26M 2.69B | Capitalization | 10.86B 68.68M 5.72B |
|---|---|---|---|---|---|
| Net income 2024 * | 810M 5.12M 426M | Net income 2025 * | 900M 5.69M 474M | EV / Sales 2024 * | 1.83 x |
| Net cash position 2024 * | 2.42B 15.33M 1.28B | Net cash position 2025 * | 2.91B 18.39M 1.53B | EV / Sales 2025 * | 1.56 x |
| P/E ratio 2024 * |
13.4
x | P/E ratio 2025 * |
12.1
x | Employees | 471 |
| Yield 2024 * |
1.66% | Yield 2025 * |
1.99% | Free-Float | 25.8% |
More Fundamentals
* Assessed data
| 1 week | -0.77% | ||
| Current month | -1.95% | ||
| 1 month | -3.94% | ||
| 3 months | -2.38% | ||
| 6 months | -13.17% | ||
| Current year | -2.80% |
1 week
4 515.00
4 615.00
1 month
4 515.004 670.00
Current year
4 480.004 925.00
1 year
4 480.006 580.00
3 years
3 205.007 800.00
5 years
1 752.007 800.00
10 years
1 752.007 800.00
| Managers | Title | Age | Since |
|---|---|---|---|
| President | 49 | 01/14/01 | |
Soko Fujiwara
ADM | Chief Administrative Officer | 47 | 01/11/01 |
Hatsune Hirako
BRD | Director/Board Member | 41 | 01/14/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 01/11/01 | |
| President | 49 | 01/14/01 | |
Hatsune Hirako
BRD | Director/Board Member | 41 | 01/14/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 4,515 | 0.00% | 400 |
| 25/24/25 | 4,515 | -0.22% | 600 |
| 24/24/24 | 4,525 | -1.20% | 1,400 |
| 23/24/23 | 4,580 | -0.11% | 100 |
| 22/24/22 | 4,585 | +0.77% | 300 |
Delayed Quote Japan Exchange, April 26, 2024 at 11:30 am IST
More quotes
WDB coco CO., LTD. is a Japan-based company engaged in the contract development of pharmaceutical companies. The Company is engaged in the provision of safety information management service as an agent and support for drug development, document support service, development support service and clinical development support service. The safety information management service provides support services such as input, evaluation drafting and report drafting. The document support service provides support services from QC (quality assurance) and translation of documents and materials necessary for marketing approval to PMDA (Pharmaceuticals and Medical Devices Agency) to the creation of approval application called CTD (Common Technical Document). The development support service provides services such as survey form management, filing of survey-related documents and call center operations. The clinical development support service provides support services for clinical trial related work.
Sector
Business Support Services
Calendar
10/05/2024
- Q4 2023 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.80% | 68.98M | |
| +10.55% | 67.6B | |
| +11.64% | 18.21B | |
| +21.03% | 13.41B | |
| +9.40% | 13.37B | |
| +16.53% | 9.94B | |
| -32.90% | 5.74B | |
| -10.98% | 5.57B | |
| -4.09% | 4.91B | |
| -4.83% | 4.87B |
- Stock Market
- Equities
- 7079 Stock
